Fighting Cancer with Personalized Vaccines: OncoDNA and myNEO Join Forces to Unlock the Power of mRNA Therapeutics
OncoDNA, a theranostic and genomic company specializing in precision medicine, and myNEO, an AI-driven company revolutionizing target identification within immuno-oncology, are thrilled to announce a new collaboration that will revolutionize cancer care. The two companies agreed to consolidate their core technologies to enable the production of personalized vaccines for patients who have run out of treatment options.
With the COVID-19, the field of mRNA therapeutics has been moving faster than ever before. In oncology, personalized vaccines can help fight cancer by selectively boosting the immune system. These vaccines can teach the body to recognize and eliminate tumor-specific neoantigens.
OncoDNA and myNEO will leverage their sequencing and bioinformatics technologies to identify and select the most effective neoantigens to target in a patient. While OncoDNA will perform whole genome and whole transcriptome sequencing, myNEO will handle the advanced interpretation of the sequenced data and design the optimal vaccine construct for maximum clinical benefit.
The project promises to guide patients through a completely personalized journey. The eligible patients would receive tailor-made vaccines as well as personalized follow-up by monitoring circulating tumor DNA after inoculation. With its OncoFOLLOW™ liquid biopsy, OncoDNA will help monitor the patient response and the evolution of the cancer very closely using personalized next-generation sequencing method.
“OncoDNA is delighted to jump with myNEO into this ambitious project. We stand at the forefront of innovation and the challenges ahead are herculean. Together we will work towards a world where patients with a hard-to-treat disease will have the opportunity to design their personalized elixirs. It may take years before this technology becomes a reality. However, the ongoing pilot tests on patients who do not respond to any therapy are showing promising results ”, commented Jean-Pol Detiffe, Chief Strategy & Innovation Officer and Founder of OncoDNA.
“Since day 1, myNEO’s mission has been to unlock the promise of immunotherapy via deep genomic and immune profiling of tumors,” described Cedric Bogaert, co-founder and CEO of myNEO. “Currently, our technology is used by biopharma partners to design the upcoming breakthrough immuno-oncology therapies. This project takes our ambition one step further in enabling OncoDNA’s vast network of clinicians and patients to directly benefit from this deep genomic and immune profiling. As such, this project holds great potential to make individualized immunotherapies more accessible to patients.”
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NV-WESTFALL-TECHNIK19.4.2021 03:21:04 CEST | Press release
Former Flex Executive Paul Humphries Joins Westfall Technik’s Board of Directors
NIELSENIQ19.4.2021 03:02:04 CEST | Press release
NielsenIQ and J.D. Power Enter Strategic Alliance to Bring Unparalleled Automotive Research to Major Growth Markets
MANCHESTER-UNITED19.4.2021 00:24:10 CEST | Press release
Leading European Football Clubs Announce Participation in New Super League Competition
BOLLÉ-SAFETY16.4.2021 22:02:13 CEST | Press release
Advanced Eye Protection Against Covid-19 For Healthcare Professionals – an Exclusive Bollé Safety Technology
ZEEPAY16.4.2021 19:57:10 CEST | Press release
Zeepay Ghana Acquires Mangwee Mobile Money in Zambia
CGTN16.4.2021 18:31:06 CEST | Press release
CGTN: Leading With Action: China in the Fight for Carbon-Neutral Future
NY-COLICITY-INC16.4.2021 15:32:08 CEST | Press release
Colicity Inc. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about April 16, 2021
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom